Lung CD4+ T cells displayed significantly increased Th1 (IFNγ) and Th2 (IL-4, IL-5, IL-13) cytokine production potential during pre-patent infection at the higher dose (Fig. 3D). The gene discussed is IL5; the disease is infection.